Stem Cells and Vaccines in Biomanufacturing

November 2009. Dr Majid Mehtali, at the time CSO of Vivalis gives a personal perspective on demand for stem cell application, in particular in biomanufacturing. In the exclusive interview with B2Bioworld he outlines Vivalis’ expansion strategies and answers questions on financing and cash burn.

In May 2013 Vivalis merged with Austrian Intercell and formed Valneva SE which significantly changed the group’s strategy. However the approach to biomanufacturing of vaccines remains. Updated 2013Reading time: 8 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section